Vitiligo treatment and therapy

Vitiligo is an acquired skin depigmentation occurring in approximately 1 percent of the population worldwide. It results from an autoimmune process directed against the melanocytes. The disease can be devastating psychologically; particularly in dark-skinned individuals. The pathogenesis is thought to involve an autoimmune process directed against melanocytes. Evidence of this is derived from histologic studies that have found an absence of melanocytes in the affected skin. An autoimmune process is also suggested by the concomitant occurrence of other autoimmune diseases in patients with vitiligo. 

  • pathogenesis of vitiligo
  • mechanism of regimentation in vitiligo
  • classification of vitiligo
  • medical treatment of vitiligo

Related Conference of Vitiligo treatment and therapy

April 10-11, 2025

27th World Dermatology and Aesthetic Congress

Dubai, UAE
May 20-21, 2025

30th International Conference on Dermatology & Skin Care

Zurich, Switzerland
June 12-13, 2025

8th World Cosmetic and Dermatology Congress

London, UK
July 28-29, 2025

25th European Dermatology Congress

Paris, France
August 20-21, 2025

26th World Dermatology Congress

Paris, France
August 21-22, 2025

8th International Dermatology and Cosmetology Congress

Dublin, Ireland
September 15-16, 2025

24th International Conference on Dermatology and Skin Care Sciences

Aix-en-Provence, France

Vitiligo treatment and therapy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in